Xbrane Biopharma AB (XBRANE) AI Stock Analysis

• Market Cap: kr379.37M
• Dividend Yield: N/A
• Average Volume (3M): 18.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.19
• Revenue Growth: 45.52%
• EPS Growth: 93.35%
• Country: SE
• Employees: 65
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): <0.01
• Shares Outstanding: 1,532,190,300
• 10 Day Avg. Volume: 10,081,940
• 30 Day Avg. Volume: 18,199,114
• PEG Ratio: -0.02
• Price to Book (P/B): 1.12
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.26
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: kr0.50 ▲(100.00%Upside)

Xbrane Biopharma AB's stock score is driven primarily by its financial challenges, with significant losses and negative cash flow impacting the score. Although there is positive technical momentum, the lack of profitability and unattractive valuation significantly weigh down the overall score. The company must demonstrate improved financial performance and profitability to enhance its stock appeal.

Xbrane Biopharma AB Business Overview & Revenue Model

Company Description

Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.

How the Company Makes Money

Xbrane Biopharma AB generates revenue primarily through the development and commercialization of biosimilar products. The company's revenue model involves partnering with larger pharmaceutical firms to advance biosimilar candidates through clinical trials and regulatory approval processes. These partnerships often include licensing agreements, where Xbrane receives upfront payments, milestone payments, and royalties based on the sale of approved biosimilar products. Additionally, Xbrane may earn revenue from contract development services and collaborations with other biopharmaceutical companies, leveraging its expertise in biosimilar development to support third-party projects. Strategic alliances and out-licensing deals are significant contributors to Xbrane's earnings, enabling the company to share the financial risks and benefits associated with bringing biosimilars to market.

Xbrane Biopharma AB Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
198.70M	238.73M	57.62M	11.53M	6.82M
	Gross Profit
180.47M	35.39M	41.04M	-684.00K	2.45M
	EBIT
-217.92M	-310.43M	-166.22M	-180.40M	-224.25M
	EBITDA
-181.97M	-282.03M	-149.34M	-167.59M	-213.07M
	Net Income Common Stockholders
-266.22M	-388.17M	-172.23M	-191.01M	-226.79M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
124.33M	65.40M	193.99M	295.18M	243.14M
	Total Assets
842.43M	653.51M	690.51M	688.43M	463.76M
	Total Debt
191.72M	231.48M	38.22M	44.38M	6.26M
	Net Debt
67.39M	166.08M	-155.77M	-250.80M	-236.88M
	Total Liabilities
633.89M	482.17M	265.63M	256.69M	206.06M
	Stockholders Equity
208.54M	171.34M	424.89M	431.74M	257.71M
Cash Flow		Free Cash Flow
-185.97M	-423.45M	-254.04M	-296.96M	-242.26M
	Operating Cash Flow
-133.73M	-406.68M	-193.92M	-219.61M	-238.41M
	Investing Cash Flow
-52.25M	-16.77M	-60.13M	-77.35M	-3.85M
	Financing Cash Flow
243.62M	298.70M	148.86M	349.37M	322.72M

Xbrane Biopharma AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XBRANE, the sentiment is Positive. The current price of 0.25 is above the 20-day moving average (MA) of 0.24, above the 50-day MA of 0.22, and above the 200-day MA of 0.19, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.89 is Neutral, neither overbought nor oversold. The STOCH value of 63.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:XBRANE.

Xbrane Biopharma AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.31B	3.26	-45.10%	2.79%	16.76%	0.02%
XBRANE	48 Neutral	kr379.37M	―	-47.73%	―	45.52%	93.35%
IMMU	44 Neutral	kr267.41M	―	-18.79%	―	―	21.85%
IVACC	42 Neutral	€367.40M	―	-24.61%	―	47.06%	33.86%
ONCO	40 Underperform	kr321.97M	―		―	1.72%	32.54%
ISOFOL	36 Underperform	€185.74M	―	-54.29%	―	-100.00%	-17.35%
GUARD	32 Underperform	kr375.12M	―	-205.65%	―	―	24.25%

Xbrane Biopharma AB Corporate Events

Xbrane Biopharma Strengthens Focus with Sale of XB003 to Alvotech

Xbrane Biopharma has completed the sale of its biosimilar candidate XB003 and parts of its organization to Alvotech for approximately SEK 275 million. This transaction strengthens Xbrane’s financial position, allowing the company to focus on its remaining programs, particularly Ximluci and Xdivane, and continue its work in biosimilar development to create value for shareholders and patients.

Xbrane Biopharma Advances Biosimilar Candidate Towards FDA Approval

Xbrane Biopharma AB has re-submitted its Biologics License Application to the US FDA for its biosimilar candidate to LUCENTIS® (ranibizumab), aimed at treating conditions such as age-related macular degeneration. The FDA has set a decision date for October 2025, contingent on successful re-inspections of manufacturing sites. This move underscores Xbrane’s commitment to providing cost-effective treatment alternatives and could enhance its position in the biosimilar market.

Xbrane Biopharma Strengthens Financial Position with Strategic Asset Sale

Xbrane Biopharma AB announced a strategic move to sell its biosimilar candidate XB003 and parts of its organization to Alvotech for approximately SEK 275 million. This transaction is expected to strengthen Xbrane’s financial position by reducing annual fixed costs by around SEK 120 million and allowing the company to focus on its core products, Ximluci® and Xdivane™, which are anticipated to generate significant revenue through royalties and profit sharing. The company also reported strong growth for Ximluci® in Europe and is progressing with regulatory processes in the US, while preparing for a clinical trial for Xdivane™.

Xbrane Biopharma AB Announces Key Resolutions from Annual General Meeting

Xbrane Biopharma AB’s annual general meeting resulted in several key resolutions, including the adoption of the income statement and balance sheet, the decision not to distribute dividends, and the re-election of board members and auditors. The meeting also established remuneration for directors and committee members and set guidelines for senior executive remuneration, while withdrawing a proposal for issuing shares due to insufficient support.